No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Japan Medical Dynamic Marketing, Inc. (JMDM) engages in the development, production, importation, and distribution of medical instruments throughout Japan and the United States. Its product portfolio features a variety of trauma devices, including surgical nails, screws, and plates, engineered for implantation at fracture sites. JMDM also offers joint prostheses, which are designed to replace compromised natural joints and restore functions impaired by disease or injury. Additionally, the company supplies spinal stabilization systems for operations addressing spinal instability, as well as synthetic bone grafts used in the treatment of bone fractures, tumors, and other structural deficiencies. These specialized medical solutions are provided to healthcare professionals and hospitals. Founded in 1973, the firm's headquarters are located in Tokyo, Japan.
www.jmdm.co.jpNo one on the platform currently holds 7600.T.
No tracked institution reports a position in 7600.T as of their last filing.
No one on the platform has traded 7600.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.1% | — | — | — | ||
| Rev. Growth % | -4.8% | 7.4% | ||||
| Profit Margin % | 1.1% | 4.5% | 7.4% | |||
| Free Cash Flow Margin % | -7.3% | 0.8% | 3.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $22.0B | -10.2% | $-40.60 | $-40.60–$-40.60 | — | 1 |
| 2028 | $22.5B | +2.3% | $3.00 | $3.00–$3.00 | — | 1 |
| 2029 | $24.0B | +6.7% | $7.60 | $7.60–$7.60 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| -2.97% |
| $8.2B |
| — |
| 4579.TRaQualia Pharma Inc. | $568.00 | +1.43% | $13.9B | — |
| 6678.TTechno Medica Co., Ltd. | $2057.00 | +0.78% | $13.7B | — |
Source: Financial Modeling Prep · peers by sector/industry